ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Hold Rating from Analysts at Deutsche Bank Aktiengesellschaft

Research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research report issued on Tuesday,Briefing.com Automated Import reports. The brokerage set a “hold” rating and a $22.00 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 16.53% from the company’s previous close.

A number of other research firms have also recently issued reports on ACAD. Guggenheim cut ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

ACADIA Pharmaceuticals Trading Up 1.8 %

NASDAQ:ACAD opened at $18.88 on Tuesday. ACADIA Pharmaceuticals has a 1 year low of $14.15 and a 1 year high of $26.78. The stock has a market cap of $3.14 billion, a price-to-earnings ratio of 24.21 and a beta of 0.37. The stock has a 50-day moving average price of $17.80 and a two-hundred day moving average price of $16.65.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 10,329 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $173,630.49. Following the sale, the chief operating officer now owns 62,105 shares in the company, valued at $1,043,985.05. This represents a 14.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Mark C. Schneyer sold 10,259 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $172,453.79. Following the completion of the sale, the chief financial officer now owns 53,302 shares in the company, valued at $896,006.62. This represents a 16.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,661 shares of company stock worth $414,551 over the last 90 days. Company insiders own 28.30% of the company’s stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Large investors have recently made changes to their positions in the company. SG Americas Securities LLC increased its stake in shares of ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock worth $45,576,000 after purchasing an additional 1,966,607 shares during the period. Barclays PLC grew its position in ACADIA Pharmaceuticals by 126.2% during the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock worth $4,269,000 after buying an additional 154,854 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in ACADIA Pharmaceuticals during the third quarter worth approximately $483,000. Burney Co. acquired a new stake in ACADIA Pharmaceuticals during the fourth quarter worth approximately $6,953,000. Finally, BNP Paribas Financial Markets grew its position in ACADIA Pharmaceuticals by 259.0% during the third quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock worth $3,439,000 after buying an additional 161,331 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.